Cargando…
Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy
Many basic research studies have shown the potential of autologous cancer vaccines in the treatment of melanoma. However, some clinical trials showed that simplex whole tumor cell vaccines can only elicit weak CD8(+) T cell-mediated antitumor responses which were not enough for effective tumor elimi...
Autores principales: | Yang, Kui, Zhou, Yuhan, Huang, Biwang, Zhao, Guifang, Geng, Yuan, Wan, Chao, Jiang, Fagang, Jin, Honglin, Ye, Chengzhi, Chen, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044724/ https://www.ncbi.nlm.nih.gov/pubmed/36998647 http://dx.doi.org/10.1039/d2na00911k |
Ejemplares similares
-
Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy
por: Zhou, Yuhan, et al.
Publicado: (2021) -
CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021) -
Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma
por: Gershan, Jill A., et al.
Publicado: (2015) -
Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
por: van den Boorn, Jasper G., et al.
Publicado: (2010) -
Antibody targeted CpG for the immunotherapy of solid tumors
por: Epstein, Alan L, et al.
Publicado: (2015)